Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.00 EUR
9.07 M EUR
266.39 M EUR
45.02 M
About TAKARA BIO INC
Sector
Industry
Website
Headquarters
Kusatsu
Founded
1925
ISIN
JP3460200003
FIGI
BBG000RHK456
Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. It provides products and services for basic research and industrial application in life sciences. These include services for the research and manufacturing of regenerative medicine products and the development of gene therapy products for synovial sarcoma. It also develops, manufactures, and sells reagents for polymerase chain reaction (PCR) tests for COVID-19. The company was founded on April 1, 2002 and is headquartered in Kusatsu, Japan.
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange TAKARA BIO INC. stocks are traded under the ticker TF2.
We've gathered analysts' opinions on TAKARA BIO INC. future price: according to them, TF2 price has a max estimate of 7.44 EUR and a min estimate of 5.58 EUR. Watch TF2 chart and read a more detailed TAKARA BIO INC. stock forecast: see what analysts think of TAKARA BIO INC. and suggest that you do with its stocks.
Yes, you can track TAKARA BIO INC. financials in yearly and quarterly reports right on TradingView.
TAKARA BIO INC. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
TF2 earnings for the last quarter are −0.10 EUR per share, whereas the estimation was −0.04 EUR resulting in a −161.83% surprise. The estimated earnings for the next quarter are 0.10 EUR per share. See more details about TAKARA BIO INC. earnings.
TAKARA BIO INC. revenue for the last quarter amounts to 58.51 M EUR, despite the estimated figure of 68.21 M EUR. In the next quarter, revenue is expected to reach 95.68 M EUR.
TF2 net income for the last quarter is −11.62 M EUR, while the quarter before that showed 9.75 M EUR of net income which accounts for −219.19% change. Track more TAKARA BIO INC. financial stats to get the full picture.
TAKARA BIO INC. dividend yield was 1.75% in 2023, and payout ratio reached 138.31%. The year before the numbers were 2.42% and 31.59% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of May 11, 2025, the company has 1.84 K employees. See our rating of the largest employees — is TAKARA BIO INC. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TAKARA BIO INC. EBITDA is 35.54 M EUR, and current EBITDA margin is 18.44%. See more stats in TAKARA BIO INC. financial statements.
Like other stocks, TF2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TAKARA BIO INC. stock right from TradingView charts — choose your broker and connect to your account.